Venous thromboembolism (VTE) is a serious condition where blood clots form inside the veins and block normal blood flow. This condition includes two main forms: deep vein thrombosis, when a clot develops in a deep vein, usually in the leg or arm, and pulmonary embolism, when a clot breaks free and travels to the lungs. Understanding how these clots are treated—both with established methods and with new therapies being tested in clinical trials—can help patients and their families navigate the journey from diagnosis to recovery.

How Treatment Helps Control Blood Clots and Prevent Serious Complications

The primary goal when treating venous thromboembolism is to stop the blood clot from growing larger and to prevent it from breaking apart and traveling to other organs, particularly the lungs. Treatment also aims to reduce the chances of another clot forming in the future.^[1] When a blood clot blocks a vein, blood can pool behind the blockage, causing swelling and inflammation. If left untreated, the clot can damage the vein permanently or move through the bloodstream to the lungs, creating a life-threatening situation called pulmonary embolism.^[2]

The approach to treatment depends on several factors, including where the clot is located, how large it is, the patient’s overall health, and whether there are other medical conditions present. For example, someone who has had recent surgery or a traumatic injury may need a different treatment plan than someone whose clot appeared without any clear trigger.^[3] The stage of the disease also matters. A small clot in the leg may be managed differently than a large clot that has already reached the lungs. Healthcare providers consider all these factors when deciding which medications or procedures will work best for each person.

Current treatment guidelines, developed by medical societies and research organizations, recommend that most patients receive anticoagulation therapy, which means using medications that prevent the blood from clotting too easily. These are often referred to as blood thinners. Beyond established treatments, researchers are continuously studying new drugs and innovative therapies in clinical trials to find safer and more effective ways to treat venous thromboembolism.^[9]

Standard Medical Treatment: Medications and Procedures That Have Proven Effective

For decades, the cornerstone of venous thromboembolism treatment has been anticoagulant medication. These drugs do not dissolve existing clots, but they prevent clots from growing and stop new ones from forming. The body’s natural mechanisms can then gradually break down the clot over time.^[9] There are several types of blood thinners, and the choice depends on the patient’s individual situation.

One of the oldest and most widely used blood thinners is heparin. Heparin is usually given through an injection under the skin or through an intravenous line directly into a vein. There are two main forms: unfractionated heparin and low-molecular-weight heparin. Unfractionated heparin is typically used when a patient is in the hospital, especially if they are hemodynamically unstable, have severe kidney problems, are at high risk of bleeding, or are morbidly obese. Low-molecular-weight heparin is more convenient because it can be given as a shot under the skin once or twice a day, and many patients can use it at home.^[9][14]

Another well-known blood thinner is warfarin, which is taken by mouth. Warfarin has been used for many years and is effective at preventing clots. However, it requires careful monitoring because the dose needs to be adjusted based on regular blood tests that measure something called the international normalized ratio, or INR. This test shows how long it takes the blood to clot. Patients taking warfarin need to be cautious about their diet, especially with foods high in vitamin K, such as kale, spinach, and Brussels sprouts, because these can affect how the drug works. Green tea, cranberry juice, and alcohol can also interfere with warfarin.^[12][22]

When warfarin is used, it must be started together with heparin because warfarin takes several days to reach its full effect. The heparin is continued for at least five days or until the INR blood test shows that warfarin is working properly for at least 24 hours.^[12][14]

In recent years, newer medications called direct-acting oral anticoagulants, or DOACs, have become available. These include drugs like dabigatran, edoxaban, rivaroxaban, and apixaban. These medications are taken by mouth and do not require the frequent blood testing that warfarin does. They also have fewer interactions with food. For these reasons, they are often more convenient for patients. However, they can be more expensive, and until recently, reversing their effects in case of serious bleeding was challenging. A reversing agent is now available for dabigatran, and others are being developed.^[9][14]

Some of these newer drugs, such as dabigatran and edoxaban, need to be started after a patient has already been treated with a parenteral anticoagulant—a medication given by injection or IV—for five to ten days. Other DOACs can be started right away without the need for initial heparin treatment.^[14]

For patients with very large or severe blood clots that cause life-threatening symptoms, doctors may use stronger medications called thrombolytics, also known as clot-busting drugs. These medicines work by actively dissolving the clot, but they carry a high risk of sudden and serious bleeding. For this reason, thrombolytics are reserved for emergency situations, such as a massive pulmonary embolism, where the benefits outweigh the risks. They are given through an IV in a hospital setting.^[9][5]

In addition to medications, some patients may need a procedure to remove the clot. One such procedure is catheter-assisted thrombus removal. During this procedure, a thin, flexible tube called a catheter is inserted into a vein, usually in the leg or arm, and guided to the site of the clot using imaging technology. The catheter can deliver medication directly to the clot or be used with special tools to break up or remove the clot. This approach allows for more targeted treatment and may reduce the dose of medication needed, which can lower the risk of bleeding.^[9][15]

Another option for certain patients is the placement of an inferior vena cava filter, or IVC filter. This is a small device inserted into the large vein that carries blood from the lower body to the heart. The filter is designed to catch blood clots before they can reach the lungs. However, filters are not a substitute for anticoagulation. They are typically used only in patients who cannot take blood thinners due to a high risk of bleeding. When possible, the filter should be removed once it is no longer needed.^[5][15]

Current guidelines recommend that most patients with venous thromboembolism should be treated with anticoagulant therapy for at least three months. The exact duration depends on the cause of the clot and the patient’s risk of having another clot. For example, if the clot was caused by a temporary risk factor, such as surgery or a long flight, three months of treatment may be enough. However, if the clot occurred without a clear cause, or if the patient has certain genetic or medical conditions that increase clotting risk, longer-term or even lifelong treatment may be necessary.^[9][13][14]

Special situations require tailored approaches. For instance, pregnant women and cancer patients often need to use low-molecular-weight heparin or unfractionated heparin instead of oral blood thinners because these are safer in their circumstances.^[14] Cancer patients, in particular, have a higher risk of blood clots and may need to continue anticoagulation for as long as they are receiving cancer treatment or even longer.^[19]

Patients who have a blood clot often experience side effects from treatment. The most common concern is bleeding, which can range from minor bruising or nosebleeds to more serious internal bleeding. It is important to watch for signs such as unusual bruising, bleeding that does not stop, blood in the urine or stool, or severe headaches. If any of these occur, medical attention is needed right away.^[12][21]

In some cases, supportive measures are used alongside medication. For example, compression stockings are special tight-fitting socks that apply pressure to the legs. They help improve blood flow and reduce swelling after a deep vein thrombosis. Wearing these stockings can also help prevent long-term complications like post-thrombotic syndrome, which causes chronic pain and swelling in the affected leg.^[9][3]

Most patients with uncomplicated deep vein thrombosis, and even some with low-risk pulmonary embolism, can be treated safely at home rather than in the hospital. This is especially true when low-molecular-weight heparin or direct-acting oral anticoagulants are used, as these do not require continuous intravenous infusion or frequent blood tests.^[14] Home treatment allows patients to recover in a more comfortable environment and reduces healthcare costs.

Innovative Therapies Being Tested in Clinical Trials

While current treatments for venous thromboembolism are effective for many patients, researchers are continually working to develop new therapies that are safer, more convenient, or more effective. Clinical trials are research studies that test new medications, procedures, or treatment strategies in people to see if they work better than existing options or have fewer side effects.

Clinical trials are conducted in phases. Phase I trials focus on safety. They involve a small number of participants and aim to determine if a new drug or treatment is safe and to identify the right dose. Phase II trials involve more participants and assess whether the treatment is effective and continue to monitor safety. Phase III trials compare the new treatment to the current standard of care in a large group of patients to see if it is better, as good as, or has fewer side effects. Finally, Phase IV trials are done after a treatment is approved and are used to monitor long-term effects and gather additional information about risks and benefits.^[28]

Many of the current direct-acting oral anticoagulants were developed and tested through large clinical trials before being approved for use. These trials showed that drugs like rivaroxaban, apixaban, dabigatran, and edoxaban were at least as effective as warfarin for preventing clots and had a similar or lower risk of bleeding. Because of these results, these medications are now considered a standard option for treating venous thromboembolism.^[14]

Ongoing research is exploring even newer anticoagulants and refining the use of existing ones. For example, scientists are studying whether lower doses of anticoagulants can be used for long-term prevention of recurrent clots after the initial three-month treatment period. This could reduce the risk of bleeding while still protecting patients from another clot.

Another area of active research involves understanding which patients are at highest risk for recurrent clots and who might benefit from extended or lifelong anticoagulation. Researchers are studying biomarkers—substances in the blood that can indicate disease or risk—that might help doctors predict which patients need longer treatment.

Innovative procedures are also being tested. One example is the use of advanced catheter-based techniques to remove clots more effectively and with fewer complications. These procedures use imaging guidance and specialized tools to break up or suction out large clots. Some trials are testing the use of ultrasound-assisted thrombolysis, where ultrasound waves help medications penetrate the clot more effectively, allowing for lower doses of clot-busting drugs and potentially reducing bleeding risk.^[15]

Researchers are also investigating the role of antiplatelet agents, which are drugs that prevent blood cells called platelets from sticking together. While anticoagulants work mainly on the clotting proteins in the blood, antiplatelet drugs like aspirin work by a different mechanism. Some studies are looking at whether adding low-dose aspirin to anticoagulation might provide additional protection against recurrent clots, particularly after the main treatment period is finished.

Clinical trials for venous thromboembolism are being conducted in many countries, including the United States, Europe, and other regions around the world. Patients who are interested in participating in a clinical trial should talk to their healthcare provider. Participation in a trial can give patients access to new treatments before they are widely available and contribute to medical knowledge that can help others in the future.^[1]

Most common treatment methods

• Blood thinners (anticoagulants)
  • Heparin given by injection or IV, including unfractionated heparin and low-molecular-weight heparin
  • Warfarin taken by mouth, requires regular blood tests to monitor INR
  • Direct-acting oral anticoagulants (DOACs) such as rivaroxaban, apixaban, dabigatran, and edoxaban, taken by mouth without frequent blood tests
  • Treatment typically lasts at least three months, but may be longer depending on risk factors
• Thrombolytic therapy (clot-busting drugs)
  • Used for large blood clots causing severe symptoms or life-threatening pulmonary embolism
  • Given through IV in emergency situations
  • Carries high risk of bleeding, reserved for serious cases
• Catheter-based procedures
  • Catheter-assisted thrombus removal uses a thin tube to deliver medication directly to the clot or remove it with special tools
  • Image-guided technology helps position the catheter accurately
  • May reduce medication doses and bleeding risk
• Inferior vena cava (IVC) filters
  • Small device placed in the large vein to trap clots before they reach the lungs
  • Used only for patients who cannot take blood thinners
  • Should be removed when no longer needed
  • Not a substitute for anticoagulation therapy
• Compression therapy
  • Compression stockings apply pressure to the legs to improve blood flow
  • Helps reduce swelling and prevent long-term complications like post-thrombotic syndrome

Preventing Future Blood Clots and Supporting Recovery

After treatment for venous thromboembolism, taking steps to prevent future clots is essential. Patients who have had one clot are at higher risk of having another, so long-term preventive measures are important.^[3] The risk of recurrence depends on what caused the first clot. If it was related to a temporary situation like surgery, the risk may be lower than if the clot occurred without any clear trigger.

Lifestyle changes can make a significant difference in reducing the risk of future clots. Staying physically active is one of the most important steps. Regular movement helps keep blood flowing and prevents it from pooling in the veins. After a blood clot, gentle activities like walking or swimming can help with recovery and improve circulation. Over time, patients can gradually increase their activity level. For those who had a pulmonary embolism, exercises that get the heart pumping can actually strengthen the lungs.^[17][22]

Avoiding prolonged periods of sitting is also crucial. People who sit for more than two hours at a time, whether at work, on a long flight, or during a car trip, should try to get up and move around regularly. If you cannot stand, flexing the ankles and doing simple leg exercises can help keep blood moving. On long flights or car trips lasting more than three hours, it is important to walk around every hour or so, drink plenty of fluids, and avoid crossing the legs while seated.^[18][22]

Maintaining a healthy weight, quitting smoking, and avoiding excessive alcohol consumption are also important preventive measures. Smoking and obesity are both risk factors for blood clots. Staying hydrated is equally important, as dehydration can make the blood thicker and more likely to clot.^[7][18]

For people who have had a blood clot, wearing compression stockings as recommended by a healthcare provider can help prevent long-term complications. These stockings are particularly useful for people with deep vein thrombosis and can reduce swelling and discomfort in the legs.^[22]

Patients should also be aware of the symptoms of a new blood clot. Signs of deep vein thrombosis include swelling, pain, warmth, or redness in the leg or arm. Symptoms of pulmonary embolism include sudden shortness of breath, chest pain that worsens with deep breathing, rapid heartbeat, coughing up blood, or fainting. Anyone who experiences these symptoms should seek medical care immediately.^[3][4]

After major surgery or an injury, healthcare providers often take steps to prevent blood clots from forming in the first place. This might include giving blood-thinning medications, encouraging early movement, or using compression devices that periodically fill with air to keep blood flowing in the legs. These preventive measures are especially important for patients who are at higher risk, such as those who are older, have cancer, or have had a clot before.^[18]

Patients taking blood thinners need to be careful to avoid injuries that could cause bleeding. This means using caution when handling sharp objects, wearing gloves when using tools, and wearing protective gear during sports. It is also important to tell all healthcare providers, including dentists, that you are taking a blood thinner before any procedure.^[22]

Recovery from a blood clot can take time. Some people may experience mild pain or swelling in the affected limb for weeks or months after treatment. This is often normal, but any new or worsening symptoms should be reported to a healthcare provider. Following the treatment plan, attending all follow-up appointments, and taking medications as prescribed are essential for a full recovery.^[22]